Company profile: Gilgamesh Pharmaceuticals
1.1 - Company Overview
Company description
- Provider of novel psychotropic and psychedelic-inspired medicines for depression, bipolar depression, anxiety, stress-related disorders, and other conditions, developing compounds optimized for safety, tolerability, duration, and efficacy, including GM-1020 (oral, rapid-acting, non-dissociative NMDAR antagonist for potential at-home use), GM-2505 (short-acting 5-HT2A agonist), GM-5022 (non-hallucinogenic neuroplastogen), and GM-3009 (safer ibogaine analog for opioid use disorder, PTSD, and TBI).
Products and services
- GM-1020: Delivers an orally bioavailable, rapid-acting, non-dissociative NMDAR antagonist product enabling potential at-home use targeting depression, bipolar depression, and other conditions
- GM-5022: Engineers a non-hallucinogenic neuroplastogen therapeutic product designed for the treatment of depression, anxiety, and other conditions, intentionally avoiding hallucinatory effects
- GM-2505: Produces a short-acting 5-HT2A agonist product with 60–90 minute duration aimed at treating depression, anxiety, and other conditions
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Gilgamesh Pharmaceuticals
Keystone Heart
HQ: Israel
Website
- Description: Provider of embolic cerebral protection medical devices for cardiovascular and structural heart procedures, developing and manufacturing devices that protect the brain from emboli and reduce the risk of brain infarcts during TAVR, AF ablation, and other procedures.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Keystone Heart company profile →
Aspen Neuroscience
HQ: United States
Website
- Description: Provider of personalized, autologous iPSC-derived neuron replacement therapies for Parkinson’s disease. Pipeline includes ANPD001, a personalized cell therapy for sporadic Parkinson’s disease in IND-enabling studies, and ANPD002, a gene-corrected autologous neuron therapy targeting genetic variants, focusing on the GBA gene.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Aspen Neuroscience company profile →
BioDelivery Sciences International
HQ: United States
Website
- Description: Provider of pharmaceutical solutions focused on pain management and addiction medicine, leveraging proprietary BioErodible MucoAdhesive (BEMA) drug delivery technology to develop and commercialize new applications of proven therapies independently or through partnerships.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BioDelivery Sciences International company profile →
Newron Pharmaceuticals
HQ: Italy
Website
- Description: Provider of biopharmaceutical therapies for central and peripheral nervous system diseases, including Xadago (safinamide), an approved treatment for Parkinson’s disease available in the EU, Switzerland, the U.S., Canada, Australia, New Zealand, and Israel; and investigational candidates Evenamide as a potential first add-on therapy for positive symptoms of schizophrenia, and Ralfinamide for specific rare pain indications.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Newron Pharmaceuticals company profile →
Seaport Therapeutics
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical solutions, including the Glyph platform, a proprietary lymphatic-targeting technology enabling and enhancing oral drug administration by bypassing first-pass metabolism and reducing hepatotoxicity, and SPT-300, an oral prodrug of allopregnanolone for treating mood and anxiety disorders, including anxious depression.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Seaport Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Gilgamesh Pharmaceuticals
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Gilgamesh Pharmaceuticals
2.2 - Growth funds investing in similar companies to Gilgamesh Pharmaceuticals
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Gilgamesh Pharmaceuticals
4.2 - Public trading comparable groups for Gilgamesh Pharmaceuticals
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →